Welcome to our dedicated page for SBC Medical Group Holdings news (Ticker: SBC), a resource for investors and traders seeking the latest updates and insights on SBC Medical Group Holdings stock.
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) is frequently featured in financial and industry news as a global provider of consulting and management services to medical corporations and their clinics. News coverage of SBC often focuses on its expansion in aesthetic medicine, its multi-brand clinic strategy, and its capital markets activity as a Nasdaq-listed company included in the Russell 3000 Index.
Readers following SBC Medical news can expect updates on international expansion initiatives, such as partnerships and consulting agreements in markets like Thailand and Singapore, and strategic moves in the United States. Recent announcements include a strategic minority equity investment and collaboration framework with OrangeTwist, a U.S.-based MedSpa chain, marking SBC’s formal entry into the U.S. medical aesthetics market. News also covers partnerships with regional operators like BLEZ ASIA in Thailand, where SBC provides management support and clinical protocol guidance for new dermatology-focused clinics.
Another major category of SBC news involves corporate and capital strategy. The company issues press releases on quarterly financial results, including revenue trends, operating income, EBITDA, and key operating metrics such as the number of franchise locations and customer visits. SBC also reports on its capital strategy, including the effectiveness of a shelf registration statement on Form S-3 and authorization of a share repurchase program, as well as its inclusion in major equity indexes.
In addition, SBC news highlights strategic investments and acquisitions, such as tender offers for shares of Waqoo, Inc., a regenerative medicine-focused research and development company. These transactions are presented as part of SBC’s broader plan to enhance its healthcare technology capabilities and support long-term growth in aesthetic and related medical fields. Investors and observers can use this news feed to monitor SBC’s clinic network growth, international partnerships, and financial performance over time.
Emerging Growth Research (EGR) released an updated, company-sponsored Q2:26 research report on SBC Medical Group Holdings (NASDAQ:SBC), clarifying its paid relationship with the company and outlining recent performance and strategic initiatives. According to EGR, SBC’s Q2:26 revenue rose about 13% year-over-year to $49.2 million, with roughly 14% sequential growth, while operating profit increased about 30% year-over-year. Gross profit grew to $36.0 million from $30.0 million. EGR notes AI-driven clinic initiatives expected to add up to $15 million in H2:26 revenue, ongoing global expansion via acquisitions and partnerships in Singapore, Thailand, and the United States, and a total of 287 clinics in Japan. SBC ended Q2:26 with $185 million in cash and $38 million in debt, a Debt/Book Equity ratio of 14%, and has taken steps to improve trading liquidity, including Russell 3000 inclusion and partial reduction of founder ownership.
Emerging Growth Research released its Q2:26 update on SBC Medical Group (NASDAQ:SBC), reiterating a Buy rating and raising its 12‑month price target from $10.00 to $11.00. The firm highlights SBC’s return to revenue growth after 2025 pricing-related headwinds and franchise fee reductions.
Q2:26 revenue rose about 13% year-over-year to $49.2 million, with income from operations up roughly 30% to $19.0 million. Net income from continuing operations increased to $10.7 million from $2.4 million, and Adjusted EBITDA grew to $19.7 million from $15.3 million.
SBC’s clinic network reached 287 clinics, up 34 locations (≈13%) year-over-year, serving about 6.9 million annual visits with a 73% repeat rate. The company ended Q2:26 with approximately $185 million in cash and $38 million in commercial bank loans, implying net cash of about $147 million. According to Emerging Growth Research, SBC is expanding internationally, pursuing AI-driven initiatives that management expects could add up to $15 million in annual revenue, and trades at a discount to the firm’s DCF-derived valuation of roughly $10.66 per share.
SBC Medical (Nasdaq: SBC) reported second quarter 2026 revenue of $49 million, up 13% year-over-year, with net income attributable to SBC Medical of $11 million, up 335%. Net margin expanded to 22% and Adjusted EBITDA rose 32% to $20 million, for a 41% margin. Basic EPS was $0.10, 400% higher year-over-year, and annualized ROE reached 16%.
Growth was supported by expansion of the points business and higher service fees linked to AI-enabled support. The network reached 287 locations (up 34 year-over-year), with 6.9 million last-twelve-month visits (up 10%) and average spend per visit of $287 (up 9%). For 1H26, revenue was $92 million (+2% year-over-year), net income attributable to SBC Medical was $22 million (down 8%), and Adjusted EBITDA was $38 million (down 4%). SBC Medical held $184 million in cash and cash equivalents as of June 30, 2026.
SBC Medical (Nasdaq: SBC) will release its financial results for the second quarter ended June 30, 2026 before the U.S. market opens on August 13, 2026. Management will host an earnings conference call the same day at 8:30 a.m. Eastern Time, including a Q&A session with analysts and investors. Registration is required via the provided Zoom link. The earnings release, slide presentation, and an archived webcast will be available on SBC Medical’s Investor Relations website.
SBC Medical (Nasdaq:SBC) will open SBC MEN'S FLASH CLINIC Ikebukuro, Japan's first specialized men's beard hair removal clinic (per company research), in Tokyo on August 6, 2026.
The compact, standardized format targets high-volume beard hair removal, aims to enhance capital-efficient expansion, supports AI-native management testing, and offers a six-session course at 16,800 yen to broaden male customer entry into SBC Medical's nationwide aesthetic network.
SBC Medical (Nasdaq:SBC) will participate in multiple virtual investor conferences during May and June 2026, offering presentations and institutional 1-on-1 meetings.
Events include Lytham Partners on May 28, Noble Capital Markets on June 3–4, Emerging Growth Conference 93 on June 11, Sidoti Small Cap Conference June 17–18, and Ascent Conference Q2 Virtual Investor Summit June 24–25.
SBC Medical (Nasdaq: SBC) and consulting partner BLEZ ASIA celebrated the opening of a new aesthetic dermatology section at BLEZ CLINIC in Bangkok’s Asok district on May 21, 2026.
The section will launch services in June 2026, initially offering Japanese-quality pico laser treatments for pigmentation and spot removal, targeting Japanese expatriates and, longer term, the broader Thai and ASEAN aesthetic healthcare market.
Emerging Growth Research released its Q1:26 update on SBC Medical Group (NASDAQ:SBC), upgrading the stock to a Buy and raising its 12‑month price target to $10.00 from $9.00, versus a recent share price of $2.89.
The report cites expectations for revenue growth in 2026 after pricing headwinds, Q1:26 same‑clinic sales up 6%, customer visits up 10% to 6.7 million with a 72% repeat rate, sequential revenue and operating profit gains, $167 million cash with modest debt, 284 clinics (+13% YoY), and ongoing international expansion and AI-driven initiatives.
SBC Medical Group Holdings (Nasdaq:SBC) reported first quarter 2026 revenue of $43 million, down 9% year over year. Net income attributable to the company was $11 million, down 47%, with EPS of $0.11.
Net income margin was 26%, EBITDA was $18 million with a 43% EBITDA margin, and annualized return on equity was 18%. Franchise locations rose to 284, up 33 year over year, with 6.76 million customers in the last twelve months and a 72% repeat rate.
SBC Medical (Nasdaq: SBC) will release its first-quarter 2026 financial results for the period ended March 31, 2026, before U.S. market open on May 14, 2026.
Management will host an earnings conference call on May 14, 2026, at 8:30 a.m. Eastern Time with a Q&A session; the release, slides, and archived webcast will be available on the company investor relations website.